AbbVie’s Lutikizumab Meets Primary Endpoint in Phase 3 Hidradenitis Suppurativa Trial

By Public Technologies
  • AbbVie’s investigational lutikizumab met the primary goal in the Phase 3 INTREPID trial for adults and adolescents with moderate to severe hidradenitis suppurativa.
  • Treatment improved clinical response versus placebo, reduced skin pain and disease flares, with no new safety concerns identified.
  • Results will be presented at a future medical congress.
  • Additional trial data are expected in 2027 to support regulatory submissions in the second half of that year.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AbbVie Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610220900PR_NEWS_USPR_____CG74397) on October 22, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk